What we know about TMEM106B in neurodegeneration

Acta Neuropathologica

Volumn 132, Issue 5, 2016, Pages 639-651

  Nicholson, Alexandra M ^a   Rademakers, Rosa ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Frontotemporal dementia; Genetic association; Lysosomes; TDP 43; TMEM106B

Indexed keywords

CELL PROTEIN; PROGRANULIN; TAR DNA BINDING PROTEIN; TMEM106B PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; TDP-43 PROTEIN, HUMAN; TMEM106B PROTEIN, HUMAN;

ALZHEIMER DISEASE; BRAIN SIZE; CHROMOSOME 9; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HIPPOCAMPAL SCLEROSIS; HUMAN; LYSOSOME; NERVE DEGENERATION; OPEN READING FRAME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TDP 43 PROTEINOPATHY; CHROMOSOME 7; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOTYPE;

CHROMOSOMES, HUMAN, PAIR 7; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; RISK FACTORS;

EID: 84982286015     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1610-9     Document Type: Review

References (87)

1. Adams HH, Verhaaren BF, Vrooman HA, Uitterlinden AG, Hofman A, van Duijn CM et al (2014) TMEM106B influences volume of left-sided temporal lobe and interhemispheric structures in the general population. Biol Psychiatry 76:503–508
2. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445
3. Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R et al (2015) Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol 129:53–64
4. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611
5. Baizabal-Carvallo JF, Jankovic J (2016) Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol 12:175–185
6. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919
7. Boxer AL, Miller BL (2005) Clinical features of frontotemporal dementia. Alzheimer Dis Assoc Disord 19(Suppl 1):S3–S6
8. Brady OA, Meng P, Zheng Y, Mao Y, Hu F (2011) Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem 116:248–259
9. Brady OA, Zheng Y, Murphy K, Huang M, Hu F (2012) The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 22:685–695
10. Brady OA, Zhou X, Hu F (2014) Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). J Biol Chem 289:19670–19680
11. Busch JI, Martinez-Lage M, Ashbridge E, Grossman M, Van Deerlin VM, Hu F et al (2013) Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. Acta Neuropathol Commun 1:36
12. Busch JI, Unger TL, Jain N, Skrinak RT, Charan RA, Chen-Plotkin AS (2016) Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. Hum Mol Genet. doi:10.1093/hmg/ddw127
13. Cerami C, Scarpini E, Cappa SF, Galimberti D (2012) Frontotemporal lobar degeneration: current knowledge and future challenges. J Neurol 259:2278–2286
14. Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley L et al (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213–11227
15. Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N et al (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 68:581–586
16. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924
17. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256
18. Deming Y, Cruchaga C (2014) TMEM106B: a strong FTLD disease modifier. Acta Neuropathol 127:419–422
19. Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-Hernandez M et al (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76:467–474
20. Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, Muller K et al (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 18:631–636
21. Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC et al (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol 127:407–418
22. Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J et al (2006) Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 15:2988–3001
23. Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Philtjens S, Heeman B et al (2015) Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 85:2116–2125
24. Goldman JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J et al (2005) Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65:1817–1819
25. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014
26. Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G et al (2014) Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol 127:845–860
27. Henne WM, Buchkovich NJ, Emr SD (2011) The ESCRT pathway. Dev Cell 21:77–91
28. Henne WM, Stenmark H, and Emr SD (2013) Molecular mechanisms of the membrane sculpting ESCRT pathway. Cold Spring Harb Perspect Biol 5:a016766
29. Hernandez I, Rosende-Roca M, Alegret M, Mauleon A, Espinosa A, Vargas L et al (2015) Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis. J Alzheimers Dis 43:325–334
30. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H et al (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702–705
31. Isaacs AM, Johannsen P, Holm I, Nielsen JE (2011) Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res 8:246–251
32. Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M et al (2005) Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 62:925–930
33. Josephs KA, Holton JL, Rossor MN, Godbolt AK, Ozawa T, Strand K et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373
34. Jun GIbrahim-Verbaas CA, Vronskaya M, Jun GIbrahim-Verbaas JC, Chung J, Naj AC et al (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108–117
35. Jun MH, Han JH, Lee YK, Jang DJ, Kaang BK, Lee JA (2015) TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. Mol Brain 8:85
36. Knecht S, Drager B, Deppe M, Bobe L, Lohmann H, Floel A et al (2000) Handedness and hemispheric language dominance in healthy humans. Brain 123(Pt 12):2512–2518
37. Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D et al (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 287:19355–19365
38. Lattante S, Le Ber I, Galimberti D, Serpente M, Rivaud-Pechoux S, Camuzat A et al (2014) Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol Aging 35(2658):e2651–e2655
39. Lemberg MK (2011) Intramembrane proteolysis in regulated protein trafficking. Traffic 12:1109–1118
40. Lipton AM, White CL 3rd, Bigio EH (2004) Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 108:379–385
41. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E et al (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129:3081–3090
42. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113
43. Mackenzie IR, Rademakers R (2007) The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 8:237–248
44. Mackenzie IR, Shi J, Shaw CL, Duplessis D, Neary D, Snowden JS et al (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112:551–559
45. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL et al (2010) microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci USA 107:20382–20387
46. Meyer H, Weihl CC (2014) The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J Cell Sci 127:3877–3883
47. Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA et al (2014) Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 128:411–421
48. Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR et al (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122:673–690
49. Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR et al (2015) Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 74:75–84
50. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931
51. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133
52. Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes-Casey M et al (2013) TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem 126:781–791
53. Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19:983–997
54. Pottier C, Bieniek KF, Finch N, van de Vorst M, Baker M, Perkersen R et al (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130:77–92
55. Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R (2016) Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem 138:32–53
56. Premi E, Formenti A, Gazzina S, Archetti S, Gasparotti R, Padovani A et al (2014) Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. JAMA Neurol 71:216–221
57. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477
58. Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615–1621
59. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268
60. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ et al (2010) TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 75:2204–2211
61. Rollinson S, Mead S, Snowden J, Richardson A, Rohrer J, Halliwell N et al (2011) Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiol Aging 32(758):e751–e757
62. Rosso SM, Donker Kaat L, Baks T, Joosse M, de Koning I, Pijnenburg Y et al (2003) Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126:2016–2022
63. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443:780–786
64. Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA et al (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79:717–718
65. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA et al (2009) A gene network regulating lysosomal biogenesis and function. Science 325:473–477
66. Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K et al (2014) The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. Embo J 33:450–467
67. Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A et al (2010) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol 257:747–753
68. Serpente M, Fenoglio C, Clerici F, Bonsi R, Arosio B, Cioffi SM et al (2015) Transmembrane protein 106B gene (TMEM106B) variability and influence on progranulin plasma levels in patients with Alzheimer’s disease. J Alzheimers Dis 43:757–761
69. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O et al (2013) TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol 15:647–658
70. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H et al (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806–808
71. Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M et al (2012) Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 90:1102–1107
72. Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D et al (2006) Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129:3091–3102
73. Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM (2014) Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci 61:226–240
74. Urushitani M, Sato T, Bamba H, Hisa Y, Tooyama I (2010) Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res 88:784–797
75. van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker MC et al (2014) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 127:397–406
76. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42:234–239
77. van der Zee J, Gijselinck I, Pirici D, Kumar-Singh S, Cruts M, Van Broeckhoven C (2007) Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. Neurodegener Dis 4:227–235
78. van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R et al (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134:808–815
79. Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay-Falcone D et al (2011) Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 121:373–380
80. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH et al (2005) A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA 102:16426–16431
81. Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ et al (2012) Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci USA 109:15024–15029
82. Wang IF, Tsai KJ, Shen CK (2013) Autophagy activation ameliorates neuronal pathogenesis of FTLD-U mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. Autophagy 9:239–240
83. Wang X, Fan H, Ying Z, Li B, Wang H, Wang G (2010) Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett 469:112–116
84. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D et al (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36:377–381
85. Wood EM, Falcone D, Suh E, Irwin DJ, Chen-Plotkin AS, Lee EB et al (2013) Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol 70:1411–1417
86. Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA (2015) The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology 84:927–934
87. Zarow C, Sitzer TE, Chui HC (2008) Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep 8:363–370